Obinutuzumab for systemic sclerosis
Treatments studied
Part of Skin clinical trials.
This trial tests a medication called obinutuzumab to see if it can help people with systemic sclerosis (a disease that causes hardening of the skin and organs). It may reduce skin thickening and slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to be 18 or older and have a diagnosis of systemic sclerosis (a disease that causes skin and organ hardening).
- Your skin thickening must be within a certain range (score between 10 and 35 on a skin exam).
- Your disease must have started less than 8 years ago (counting from the first symptom other than Raynaud's) or you must have active disease.
- If you take certain medications for sclerosis (like mycophenolate or methotrexate), the dose must be stable for at least 2 months before the trial.
- You must not have had certain immune-suppressing treatments (like B-cell depleting drugs) within the past 9 months.
- You need to be willing to use reliable birth control (if you can become pregnant) and avoid live vaccines during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
This study tests a new drug called obinutuzumab to see if it can keep nephrotic syndrome from coming back in adults who need repeated rituximab treatments. The goal is to see if obinutuzumab works better at controlling the disease compared to current care.
This trial tests an experimental tablet called TollB-001 to see if it can help people with a type of systemic sclerosis that affects the skin and internal organs. It may reduce symptoms and slow the disease.
Hear when a new Systemic Sclerosis in Adults trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.